Cloud-based trial oversight and management solution enables transparency, flexibility and accountability, delivering confidence in clinical trial integrity
PHILADELPHIA, PA – ERT, a leading eClinical solutions provider, including high-quality patient data collection and analysis, today announced a major release of its Insights Cloud trial oversight solution, with features to optimize transparency, flexibility and accountability for clinical trial sponsors and Clinical Research Organization (CROs). Relationships between sponsors and CROs have become more complex as a result of emerging global regulations for implementing effective risk-based quality management strategies. Compliance with international guidelines has become a shared responsibility that requires a more collaborative and transparent working relationship. “While sponsors and CROs are committed to a shared vision, both parties often struggle to achieve a holistic assessment of trial progress,” said Amy Furlong, Executive Vice President of eClinical Insights at ERT. “Insights Cloud provides the central point of truth for trial oversight that works as a foundation for the transparency, flexibility and accountability that are essential to accomplishing shared goals and healthy relationships.” ERT’s Insights Cloud gives sponsors confidence in the integrity of their trials by delivering real-time holistic data views while enabling proactive monitoring of quality and compliance. CROs gain confidence with cutting-edge integration, automation, and data sharing capabilities that enable them to harmonize disparate data streams into meaningful metrics that support repeatable business processes across clients. ERT will demonstrate Insights Cloud for Sponsors and CROs at the
Drug Information Association (DIA) Annual Meeting
, June 27-29 in Philadelphia, PA. DIA Attendees can visit booth #509 to learn how they can achieve their shared goals of improved data quality, optimized processes, and regulatory compliance. For additional information, visit
http://www.ert.com/insights-cloud
.
About ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process. ERT delivers widely deployed solutions in centralized Cardiac Safety, Respiratory, and electronic Clinical Outcome Assessments (eCOA) – which includes patient-, clinician-, observer- and performance-reported outcomes – and cloud-based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. For more information see
www.ert.com
. Join ERT on
,
,
YouTube
and
.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.